CDK4 and leiomyosarcoma: A recent large cohort study of 99 patients with LMS found that CDK4 may be a key gene for leiomyosarcoma recurrence, and palbociclib, an inhibitor of CDK4, may provide a new option for targeted therapy in patients with LMS (Bohm et al., 2019).